-+ 0.00%
-+ 0.00%
-+ 0.00%

Zhitong Finance App News, Recco Bio-B (02179.HK) announced that the new drug marketing application for the new adjuvant recombinant herpes zoster vaccine REC610 (REC610) under development by the company was officially accepted by the Drug Evaluation Center of the China Drug Administration on December 29, 2025. The acceptance number is CXSS2500145. As of the date of this announcement, the candidate vaccine has successfully completed on-site inspection of drug clinical trials and on-site inspection of drug registration and production, and will continue to cooperate with supervisory authorities to advance the review.

Zhitongcaijing·07/23/2026 10:33:11
Listen to the news
Zhitong Finance App News, Recco Bio-B (02179.HK) announced that the new drug marketing application for the new adjuvant recombinant herpes zoster vaccine REC610 (REC610) under development by the company was officially accepted by the Drug Evaluation Center of the China Drug Administration on December 29, 2025. The acceptance number is CXSS2500145. As of the date of this announcement, the candidate vaccine has successfully completed on-site inspection of drug clinical trials and on-site inspection of drug registration and production, and will continue to cooperate with supervisory authorities to advance the review.